Pulling Q1 tickets now. I'll classify with the same taxonomy the Churn Predictor uses so the two numbers reconcile.

Q1 cancellations came in at 4,612 tickets from 2,941 unique subscribers — 1.57 tickets per canceling customer, which is normal (subscribers rarely cancel on the first contact). Here's the classification by month:

What's stable and what's trending:

1. "Shipping too frequent" is trending up month-over-month — Jan→Mar is +35%. This matches what Churn Predictor has been flagging on mid-tier Magnesium subscribers. It's our biggest driver and it's getting worse, not better.
2. "Duplicate of another brand" is the second-biggest driver and 100% flat. That means we're acquiring customers who already subscribe to a competitor and then lose the head-to-head. Acquisition problem, not retention problem.
3. Efficacy tickets are rare (6%) and stable — the product is fine. Churn here is about cadence and competition, not whether Verdant works.

Two representative quotes:

"I love the product but I've got two unopened bottles on the shelf and another one coming Monday. Please cancel until I finish what I have." — ticket #VRD-17901, 1 of 1,338

"Switching to a competitor that bundles magnesium + sleep in one capsule. Not a quality complaint, you're just one SKU and they're a stack." — ticket #VRD-17432, 1 of 831

Recommended next actions:

1. Fix shipping cadence first. The 30-day default on 180ct Magnesium is actively creating cancellations — Churn Predictor already drafted a "cadence reset" save-play; activate it. This alone should claw back 400+ cancellations per month.
2. Run an exit survey on "duplicate of another brand" — we don't currently ask which brand. I've drafted a 3-question Klaviyo exit survey: (1) which brand, (2) what pulled you away, (3) any chance we win you back in 90 days. Ready for Amira.
3. The 6% "other" bucket is small but worth a human eyeball — I can pull the 216 tickets for a spot-read if you want.